A Case Report of Leptomeningeal Myelomatosis and Rapid Improvement with Regimen Consisting of Daratumumab, Pomalidomide, Vincristine, Procarbazine, and Dexamethasone
Central nervous system (CNS) involvement in multiple myeloma (MM) (MM-CNS) in the form of leptomeningeal myelomatosis or brain parenchyma plasmacytoma is rare, causing challenges in clinical diagnosis and treatment. We would like to report a case of leptomeningeal myelomatosis and illustrated the ch...
Main Authors: | Jew Win Kuan, Sing Ling Chai, Pathmanathan Rajadurai, Lee Gong Lau, Joseph Uchang, Sharifah Noor Akmal Syed Husain |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2022-01-01
|
Series: | Case Reports in Hematology |
Online Access: | http://dx.doi.org/10.1155/2022/4081971 |
Similar Items
-
Efficacy and Safety of Daratumumab, Pomalidomide, and Dexamethasone (DPd) Compared to Daratumumab, Bortezomib, and Dexamethasone (DVd) in Daratumumab–Naïve Relapsed Multiple Myeloma
by: Aimaz Afrough, et al.
Published: (2023-10-01) -
Mieloma múltiplo: invasão leptomeníngea difusa Diffuse leptomeningeal involvement in multiple myelomatosis: a case report
by: N. O. Facure, et al.
Published: (1971-03-01) -
Combination chemotherapy for myelomatosis.
by: Clarke, M, et al.
Published: (1992) -
Multiagent therapy with pomalidomide, bortezomib, doxorubicin, dexamethasone, and daratumumab (“Pom‐PAD‐Dara”) in relapsed/refractory multiple myeloma
by: Xiang Zhou, et al.
Published: (2020-08-01) -
Pomalidomide- and dexamethasone-based regimens in the treatment of refractory/relapsed multiple myeloma
by: Despina Fotiou, et al.
Published: (2022-05-01)